{"groups":[{"description":"Beginning between day 100-110, patients receive oral lenalidomide once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.","id":"FG000","title":"Lenalidomide Maintenance"},{"description":"Beginning between day 100-110, patients receive oral placebo once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.\n\n(closed as of 12/17/09)","id":"FG001","title":"Placebo Maintenance"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"231"},{"groupId":"FG001","numSubjects":"229"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"231"},{"groupId":"FG001","numSubjects":"229"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"After registration, participants underwent a peripheral blood stem cell transplant. Of the 568 participants, 460 were randomized to either arm, stratified by beta2 microglobulin, prior thalidomide use and prior lenalidomide use. (108 participants dropped out prior to randomization, most common reasons include: progression, ineligible, refusal)","recruitmentDetails":"From December 2004 and July 2009, a total of 568 participants were recruited to this study."}